Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma

Although the proteasome inhibitor bortezomib (BTZ) shows excellent efficacy in multiple myeloma (MM), a fraction of patients has a suboptimal or no response to this agent. In addition, BTZ‐induced peripheral neuropathy (BiPN), a frequent side‐effect of this therapy, limits its use in some patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Maekawa, Keiko, Ri, Masaki, Nakajima, Miki, Sekine, Akihiro, Ueda, Ryuzo, Tohkin, Masahiro, Miyata, Naoki, Saito, Yoshiro, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778623/
https://www.ncbi.nlm.nih.gov/pubmed/31444836
http://dx.doi.org/10.1111/cas.14178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778623/
https://www.ncbi.nlm.nih.gov/pubmed/31444836
http://dx.doi.org/10.1111/cas.14178

Ejemplares similares